CoQ10 and sleep quality
What sleep and vigor studies showed and what is known about tolerability.
Key points
- In healthy working adults aged 30–64, ubiquinol showed no convincing advantage over placebo in self-rated sleep for the whole group over eight weeks. This trial did not demonstrate a confirmed improvement in sleep. [1] See the evidence 1
- Mild insomnia has been reported with CoQ10. If sleep worsens after starting it, discuss the supplement with a healthcare professional. [2] See the evidence 1
- In a separate eight-week study of healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in vigor. Sleep and vigor were assessed separately. [3] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Sleep and daytime vigor are assessed with different measures.
Key points
Why these conclusions
Sleep and vigor
Healthy working adults aged 30–64 received 100 mg of ubiquinol daily or placebo for eight weeks. No convincing advantage in self-rated sleep was found in the whole group. [1]
In a separate study of healthy adults aged 40 and over, 200 mg of ubiquinone or ubiquinol with food showed no convincing advantage over placebo in vigor over eight weeks. [3]
Mild insomnia and gastrointestinal disturbances are reported; short RCTs do not establish rare or long-term risks. [2]
In healthy working adults over eight weeks, no convincing advantage of ubiquinol in self-rated sleep was found in the whole group.
| Parameter | Data |
|---|---|
| Result | In healthy working adults over eight weeks, no convincing advantage of ubiquinol in self-rated sleep was found in the whole group. No significant advantage was found in the overall analysis; a subgroup signal in stress-sensitive participants does not establish an overall effect. |
| Participants | 60 healthy working adults aged 30–64; 52 in the efficacy analysis (24 versus 28) |
| Form | 100 mg/day ubiquinol |
| Dose | 100 mg/day ubiquinol |
| Dose basis | 100 mg/day ubiquinol |
| Comparator | Placebo |
| Duration | 8 weeks |
| Confidence | 2/4: Precision: No exact confidence interval for the overall contrast. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: 52 of 60 in the analysis, exploratory subgroup. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
Mild insomnia and gastrointestinal disturbances are reported; short RCTs do not establish rare or long-term risks.
Mild insomnia and gastrointestinal disturbances are reported; short RCTs do not establish rare or long-term risks. [2]
In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in vigor ratings over eight weeks.
| Parameter | Data |
|---|---|
| Result | In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in vigor ratings over eight weeks. No significant advantage was reported. The main text gives p>0.44 for secondary outcomes; the abstract gives p>0.16. |
| Participants | 150 healthy adults aged 40 and over allocated to five groups |
| Form | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose basis | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Comparator | Placebo |
| Duration | 8 weeks |
| Confidence | 2/4: Precision: Exact confidence intervals for each form versus placebo were not extracted. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [3] |
Sources
- Reduced Form of Coenzyme Q10 Relieves Daily Life Stress and Improves Sleep Quality in Healthy Subjects with High Stress Sensitivity. https://www.ubiquinol.net.au/wp-content/uploads/2025/03/KanekaUbiquinol_Research-paper_Endurance-and-recovery_-Ubiquinol-improves-sleep-quality_Morikawa_HCP_2019.pdf
- Coenzyme Q10 | NCCIH. https://www.nccih.nih.gov/health/coenzyme-q10
- A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations. https://doi.org/10.1155/jnme/5589963
Methodology: Subpages evidence-led supplement pipeline v1